Review




Structured Review

Accelrys discovery studio 3.0 software package
Discovery Studio 3.0 Software Package, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studio+3%2E0+software+package/discovery+studio+2+5/pmc12209269-48-27-32
Average 90 stars, based on 1 article reviews
discovery studio 3.0 software package - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

Software:

Article Title: Design, synthesis and biological evaluation of novel aryl-acrylic derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
Article Snippet: Two series of novel aryl-acrylic derivatives were designed, synthesized, and screened in enzymatic and cellular inhibitory activities.. All compounds showed moderate to significant potency.. The SAR analyses indicated that the semicarbazone linker is better than the 1,2,3-triazole linker.

Article Title: Synthesis, Molecular Docking Analysis and Biological Evaluations of Saccharide-Modified Thiadiazole Sulfonamide Derivatives
Article Snippet: Compound structures were built and minimized with the Accelrys Discovery Studio 3.0 software package with flexible torsions assigned, and all dihedral angles were able to freely rotate.

Article Title: Design, synthesis and biological evaluation of 9-aryl-5 H -pyrido[4,3- b ]indole derivatives as potential tubulin polymerization inhibitors
Article Snippet: The molecular docking was explored using the default settings of the Accelrys Discovery Studio 3.0 software package, as we previously reported.

Article Title: Stable H-bond networks are crucial for selective CLK1 inhibition: a computational perspective
Article Snippet: The structural data of human CLK1/3 protein were acquired from RCSB Protein Data Bank (CLK1 ID: 6G33 , CLK3 ID: 2WU6 ( )), which were imported into Discovery Studio 3.0 software package (Accelrys, San Diego, CA, United States ( )) for protein superposition and sequence alignment.

Article Title: ASPER-29 suppresses the metastasis of pancreatic cancer cells by dual inhibition of cathepsin-L and cathepsin-S.
Article Snippet: Pancreatic cancer will be the second leading cause of cancer-related mortality worldwide due to its high rate of metastasis.. Cathepsins (CATs) are effectors of invasive growth in various cancers.. Currently, targeting CATs represents an attractive strategy for the treatment of highly metastatic cancers with high CATs activity, such as pancreatic cancer.

Article Title: Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
Article Snippet: Correspondence Dongmei Zhao, Key Laboratory of Structure‐ Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, 110016 Shenyang, China.. Email: medchemzhao@163.com Abstract The abnormal expression of lysine‐specific histone demethylase 1 (LSD1) is associated with different cancer types, and LSD1 inhibitory activity seems to have high therapeutic potential in cancer treatment.. Here, we report the design, synthesis, and biochemical evaluation of novel 5‐aminotetrahydroquinoline‐based LSD1 inhibitors.

Article Title: Discovery of a novel cathepsin inhibitor with dual autophagy-inducing and metastasis-inhibiting effects on breast cancer cells.
Article Snippet: cancer-associated death in breast cancer patients.. In present, various active molecules either exhibiting novel mechanism of action such as inducing autophagy or inhibiting metastasis have been developed to address these problems.. However, the compounds exhibiting such dual functions have rarely been described.

Article Title: Discovery of 2,4-diaminopyrimidine derivatives targeting p21-activated kinase 4: Biological evaluation and docking studies.
Article Snippet: Funding information National Natural Science Foundation of China, Grant/Award Numbers: 81230077, 81872729 Abstract In this study, novel 2,4‐diaminopyrimidine derivatives targeting p21‐activated kinase 4 (PAK4) were discovered and evaluated for their biological activity against PAK4.. Among the derivatives studied, promising compounds A2, B6, and B8 displayed the highest inhibitory activities against PAK4 (IC50 = 18.4, 5.9, and 20.4 nM, respectively).. From the cellular assay, compound B6 exhibited the highest potency with an IC50 value of 2.533 μM against A549 cells.

Sequencing:

Article Title: Design, synthesis and biological evaluation of novel aryl-acrylic derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
Article Snippet: Two series of novel aryl-acrylic derivatives were designed, synthesized, and screened in enzymatic and cellular inhibitory activities.. All compounds showed moderate to significant potency.. The SAR analyses indicated that the semicarbazone linker is better than the 1,2,3-triazole linker.

Article Title: Synthesis, Molecular Docking Analysis and Biological Evaluations of Saccharide-Modified Thiadiazole Sulfonamide Derivatives
Article Snippet: Compound structures were built and minimized with the Accelrys Discovery Studio 3.0 software package with flexible torsions assigned, and all dihedral angles were able to freely rotate.

Article Title: Design, synthesis and biological evaluation of 9-aryl-5 H -pyrido[4,3- b ]indole derivatives as potential tubulin polymerization inhibitors
Article Snippet: The molecular docking was explored using the default settings of the Accelrys Discovery Studio 3.0 software package, as we previously reported.

Article Title: Stable H-bond networks are crucial for selective CLK1 inhibition: a computational perspective
Article Snippet: The structural data of human CLK1/3 protein were acquired from RCSB Protein Data Bank (CLK1 ID: 6G33 , CLK3 ID: 2WU6 ( )), which were imported into Discovery Studio 3.0 software package (Accelrys, San Diego, CA, United States ( )) for protein superposition and sequence alignment.

Article Title: ASPER-29 suppresses the metastasis of pancreatic cancer cells by dual inhibition of cathepsin-L and cathepsin-S.
Article Snippet: Pancreatic cancer will be the second leading cause of cancer-related mortality worldwide due to its high rate of metastasis.. Cathepsins (CATs) are effectors of invasive growth in various cancers.. Currently, targeting CATs represents an attractive strategy for the treatment of highly metastatic cancers with high CATs activity, such as pancreatic cancer.

Article Title: Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
Article Snippet: Correspondence Dongmei Zhao, Key Laboratory of Structure‐ Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, 110016 Shenyang, China.. Email: medchemzhao@163.com Abstract The abnormal expression of lysine‐specific histone demethylase 1 (LSD1) is associated with different cancer types, and LSD1 inhibitory activity seems to have high therapeutic potential in cancer treatment.. Here, we report the design, synthesis, and biochemical evaluation of novel 5‐aminotetrahydroquinoline‐based LSD1 inhibitors.

Article Title: Discovery of a novel cathepsin inhibitor with dual autophagy-inducing and metastasis-inhibiting effects on breast cancer cells.
Article Snippet: cancer-associated death in breast cancer patients.. In present, various active molecules either exhibiting novel mechanism of action such as inducing autophagy or inhibiting metastasis have been developed to address these problems.. However, the compounds exhibiting such dual functions have rarely been described.

Article Title: Discovery of 2,4-diaminopyrimidine derivatives targeting p21-activated kinase 4: Biological evaluation and docking studies.
Article Snippet: Funding information National Natural Science Foundation of China, Grant/Award Numbers: 81230077, 81872729 Abstract In this study, novel 2,4‐diaminopyrimidine derivatives targeting p21‐activated kinase 4 (PAK4) were discovered and evaluated for their biological activity against PAK4.. Among the derivatives studied, promising compounds A2, B6, and B8 displayed the highest inhibitory activities against PAK4 (IC50 = 18.4, 5.9, and 20.4 nM, respectively).. From the cellular assay, compound B6 exhibited the highest potency with an IC50 value of 2.533 μM against A549 cells.



Similar Products

90
Accelrys discovery studio 3.0 software package
Discovery Studio 3.0 Software Package, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studio+3%2E0+software+package/discovery+studio+2+5/pmc12209269-48-27-32
Average 90 stars, based on 1 article reviews
discovery studio 3.0 software package - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Accelrys discovery studio 3.0 software package pharmacophore generation
2D Chemical structures of 18 training set used to obtain HypoGen <t>pharmacophore</t> hypotheses.
Discovery Studio 3.0 Software Package Pharmacophore Generation, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studio+3%2E0+software+package/common+feature+pharmacophore+generation+module/pmc03615092-134-14-18
Average 90 stars, based on 1 article reviews
discovery studio 3.0 software package pharmacophore generation - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


2D Chemical structures of 18 training set used to obtain HypoGen pharmacophore hypotheses.

Journal: PLoS ONE

Article Title: Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening

doi: 10.1371/journal.pone.0059315

Figure Lengend Snippet: 2D Chemical structures of 18 training set used to obtain HypoGen pharmacophore hypotheses.

Article Snippet: The following program were used in the manuscript: Discovery Studio 3.0 software package for pharmacophore model generation (DS, Accelrys Inc., San Diego, USA); Gold 5.0 program for molecular docking (CCDC, UK); Derek 2.0.3 for the toxicities prediction (Lhasa Inc., UK); MarvinSketch 5.10.0 for the physicochemical properties prediction (Chemaxon Ltd., USA).

Techniques:

2D chemical structures of 30 test set molecules for the pharmacophore model validation.

Journal: PLoS ONE

Article Title: Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening

doi: 10.1371/journal.pone.0059315

Figure Lengend Snippet: 2D chemical structures of 30 test set molecules for the pharmacophore model validation.

Article Snippet: The following program were used in the manuscript: Discovery Studio 3.0 software package for pharmacophore model generation (DS, Accelrys Inc., San Diego, USA); Gold 5.0 program for molecular docking (CCDC, UK); Derek 2.0.3 for the toxicities prediction (Lhasa Inc., UK); MarvinSketch 5.10.0 for the physicochemical properties prediction (Chemaxon Ltd., USA).

Techniques:

Results of  pharmacophore  hypotheses generated by HypoGen.

Journal: PLoS ONE

Article Title: Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening

doi: 10.1371/journal.pone.0059315

Figure Lengend Snippet: Results of pharmacophore hypotheses generated by HypoGen.

Article Snippet: The following program were used in the manuscript: Discovery Studio 3.0 software package for pharmacophore model generation (DS, Accelrys Inc., San Diego, USA); Gold 5.0 program for molecular docking (CCDC, UK); Derek 2.0.3 for the toxicities prediction (Lhasa Inc., UK); MarvinSketch 5.10.0 for the physicochemical properties prediction (Chemaxon Ltd., USA).

Techniques: Generated

A and C, S1 and S13 binding to the active site of Hsp90, respectively. B and D, S1 and S13 mapped onto the pharmacophore model Hypo1, respectively. S1, S13 and the key residues were shown as stick. H-bond was colored in red. Hypothesis features are color-coded as follows: hydrophobic aromatic, light blue; hydrogen bond donor, violet; hydrogen bond acceptor, green.

Journal: PLoS ONE

Article Title: Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening

doi: 10.1371/journal.pone.0059315

Figure Lengend Snippet: A and C, S1 and S13 binding to the active site of Hsp90, respectively. B and D, S1 and S13 mapped onto the pharmacophore model Hypo1, respectively. S1, S13 and the key residues were shown as stick. H-bond was colored in red. Hypothesis features are color-coded as follows: hydrophobic aromatic, light blue; hydrogen bond donor, violet; hydrogen bond acceptor, green.

Article Snippet: The following program were used in the manuscript: Discovery Studio 3.0 software package for pharmacophore model generation (DS, Accelrys Inc., San Diego, USA); Gold 5.0 program for molecular docking (CCDC, UK); Derek 2.0.3 for the toxicities prediction (Lhasa Inc., UK); MarvinSketch 5.10.0 for the physicochemical properties prediction (Chemaxon Ltd., USA).

Techniques: Binding Assay